Monkeypox (Mpox)POQS-BoostedNCT07342829
Prospective Follow-up After MVA-BN Booster Vaccination
An observational study of Monkeypox (Mpox), run by Institute of Tropical Medicine, Belgium at 1 site in Belgium.
Trial summary
POQS-Boosted is a prospective observational study during which individuals who received Booster vaccination against mpox with the MVA-BN vaccine will be invited to provide biological samples at multiple times over the course of two years. Read more about this study
- Who is it for?
- Ages 18 years and olderHealthy volunteers can take part
- Conditions the study is for
- Monkeypox (Mpox)
- How many people
- 95 participants
- Where
- 1 siteBelgium
- Study dates
- 15 Jan 2026to 30 Jun 2028
- How long will I take part?
- 2 Years
- Phase
- Observational
- Are there results?
- Not yet: the study is under way
Key requirements
Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.
- Ages 18 years and older
- All sexes
- Healthy volunteers accepted
- Adult, Older adult
Study population: Individuals who received MVA-BN booster vaccination will be asked to participate in "POQS-Boosted"
Who may be able to join
- Is scheduled to receive a booster dose of MVA-BN
- ≥18 years
- Willingness to provide written informed consent
- Willingness to follow the study schedule
Who cannot join
- 1. Past or current MPXV infection
Trial locations and contacts
1 site in 1 country. Contact the study team or a site near you to ask about taking part.
About this study
Official title: Prospective On-site Study for the Immunological Follow-up of Individuals Who Received Booster Vaccination With MVA-BN Against Mpox
POQS-Boosted is a prospective observational study during which individuals who received Booster vaccination against mpox with the MVA-BN vaccine will be invited to provide biological samples at multiple times over the course of two years.
Read the detailed description
Mpox caused a worldwide outbreak in 2022 and continues to circulate worldwide and causes sporadic cases in Belgium and elsewhere. In the last 10 days, the first cases infected with the probably more virulent clade Ib MPXV have been reported from men who have sex with men in Belgium, the Netherlands, and elsewhere, indicating circulating this viral clade in sexual networks. In Belgium, vaccination against mpox was ceased at the end of 2022 and evidence showed that antibody levels against MPXV have decreased since then, raising questions about sustained protectiveness and the potential for a new mpox outbreak to emerge.
POQS-Boosted is a prospective observational study during which individuals who received Booster vaccination against mpox with the MVA-BN vaccine will be invited to provide biological samples at multiple times over the course of two years.
- Conditions
- Monkeypox (Mpox)
- Keywords
- mpox, immunology, vaccination, booster
- Medical subject headings
- Mpox, Monkeypox
What is being measured
The primary outcome is the main question the study is designed to answer.
Orthopoxvirus-specific serum binding and neutralising antibody titre
To describe the evolution of the orthopoxvirus-specific serum antibody response up to two years after MVA-BN booster vaccination
Measured: from enrollment to the end of follow up at 2 years
Secondary outcomes (2)
Orthopoxvirus-specific systemic T- and B cell-mediated immune responses to MPXV
To describe the evolution of the orthopoxvirus-specific systemic cellular immune response up to two years after MVA-BN booster vaccination
Measured: from enrollment up to 2 years
MPXV-specific IgA in saliva and anorectal samples; T and B cell-mediated immune responses to MPXV, measured on saliva and anorectal samples
To describe the evolution of the orthopoxvirus-specific mucosal antibody \& cellular immune response up to two years after MVA-BN booster vaccination
Measured: from enrolment up to two years
Timeline
From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.
- First posted15 Jan 2026
- Study start15 Jan 2026 (estimated)
- Primary completion30 Jun 2028 (estimated)
- Study completion30 Jun 2028 (estimated)
Resources
- Official record on ClinicalTrials.govThe registry entry this page is built from, with its full change history.
- Other trials for Monkeypox (Mpox)Studies of the same condition, open and under way.
- What the trial phases meanHow a treatment moves from first tests in people to approval.
More details
For doctors and researchers: how the study is designed, who runs it, and its registry IDs.
Study design
- Study type
- Observational
- Observational model
- Cohort
- Time perspective
- Prospective
- Enrolment
- 95 participants (estimated)
- Target duration
- 2 Years
Sponsor and investigators
- Lead sponsor
- Institute of Tropical Medicine, Belgium
- Sponsor type
- University, hospital or other
- Responsible party
- Sponsor
- Investigators
- Laurens Liesenborghs, MD, Principal investigator, Institute of Tropical Medicine Antwerp
IDs, dates and publications
- ClinicalTrials.gov ID
- NCT07342829
- Sponsor's protocol ID
- POQS-Boosted
- Acronym
- POQS-Boosted
- Status last verified
- Jan 2026
- First submitted
- 6 Jan 2026
- Last updated
- 20 Jan 2026
- Results posted
- No
- Data monitoring committee
- No
- FDA-regulated drug
- No
- FDA-regulated device
- No
- Individual data sharing
- Undecided
Study at a glance
From the registry record, last updated by the sponsor on 20 Jan 2026. Recruitment status is as the sponsor reported it: confirm with the study team.
- Official title
- Prospective On-site Study for the Immunological Follow-up of Individuals Who Received Booster Vaccination With MVA-BN Against Mpox
- ClinicalTrials.gov ID
- NCT07342829
- Acronym / sponsor ID
- POQS-Boosted / POQS-Boosted
- Conditions
- Monkeypox (Mpox)
- Keywords
- mpox, immunology, vaccination, booster
- Study type
- Observational
- Recruitment status
- Not yet recruiting
- Enrolment
- 95 participants (estimated)
- Lead sponsor
- Institute of Tropical Medicine, BelgiumUniversity, hospital or other
- Study start
- 15 Jan 2026 (estimated)
- Primary completion
- 30 Jun 2028 (estimated)
- Study completion
- 30 Jun 2028 (estimated)
- First posted
- 15 Jan 2026 (actual)
- Results
- Not posted in the source record
Clinical summary
The research question as the sponsor registered it. This describes what the study plans to test, not what it found.
POQS-Boosted is a prospective observational study during which individuals who received Booster vaccination against mpox with the MVA-BN vaccine will be invited to provide biological samples at multiple times over the course of two years.
Detailed description
Mpox caused a worldwide outbreak in 2022 and continues to circulate worldwide and causes sporadic cases in Belgium and elsewhere. In the last 10 days, the first cases infected with the probably more virulent clade Ib MPXV have been reported from men who have sex with men in Belgium, the Netherlands, and elsewhere, indicating circulating this viral clade in sexual networks. In Belgium, vaccination against mpox was ceased at the end of 2022 and evidence showed that antibody levels against MPXV have decreased since then, raising questions about sustained protectiveness and the potential for a new mpox outbreak to emerge.
POQS-Boosted is a prospective observational study during which individuals who received Booster vaccination against mpox with the MVA-BN vaccine will be invited to provide biological samples at multiple times over the course of two years.
Study design
- Observational model
- Cohort
- Time perspective
- Prospective
- Target follow-up
- 2 Years
Who may qualify
- Ages
- 18 years and older
- Sex
- All
- Healthy volunteers
- Accepted
- Age groups
- Adult, Older adult
- Study population
- Individuals who received MVA-BN booster vaccination will be asked to participate in "POQS-Boosted"
Key inclusion criteria (4 listed)
- Is scheduled to receive a booster dose of MVA-BN
- ≥18 years
- Willingness to provide written informed consent
- Willingness to follow the study schedule
Key exclusion criteria (1 listed)
- 1. Past or current MPXV infection
Eligibility is decided by the study team after screening; this overview does not establish that a patient qualifies. Full inclusion and exclusion criteria.
Primary outcome
Orthopoxvirus-specific serum binding and neutralising antibody titre
Time frame: from enrollment to the end of follow up at 2 years
To describe the evolution of the orthopoxvirus-specific serum antibody response up to two years after MVA-BN booster vaccination
2 secondary outcomes
Orthopoxvirus-specific systemic T- and B cell-mediated immune responses to MPXV
Time frame: from enrollment up to 2 years
MPXV-specific IgA in saliva and anorectal samples; T and B cell-mediated immune responses to MPXV, measured on saliva and anorectal samples
Time frame: from enrolment up to two years
Results and safety
This study is still under way. Results are not available in the source record yet.
Research links
- Official record on ClinicalTrials.govLast updated by the sponsor 20 Jan 2026.
- Individual participant dataSharing planned: Undecided
Related trials for Monkeypox (Mpox)
RecruitingObservational study
Evaluation of Effectiveness and Safety of LC16m8 Mpox Vaccine in the Democratic Republic of Congo (DRC)
Mpox (Monkeypox), Mpox
Enrolling by invitationObservational study
New York City Observational Study of Mpox Immunity
Monkeypox, Mpox
Enrolling by invitation
Smart Analysis and Decision-Making for Emerging Infectious Diseases
Emerging Infectious Diseases, COVID-19
Active, not recruitingPhase 4
Smallpox Vaccine for Mpox Post-Exposure Prophylaxis: A Cluster RCT
Monkeypox
RecruitingPhase 2
A Randomized Clinical Trial Investigating the Safety, Reactogenicity, and Immunogenicity After Immunization With an mRNA-based Mpox Vaccine Candidate in Africa
Mpox (Monkeypox), Smallpox
Referral and contact
AzTrials does not enrol participants or take referrals. Contact the study team or a site listed below; they decide who can take part.
Laurens Liesenborghs, MD principal investigator
Institute of Tropical Medicine Antwerp
1 site in 1 country: see every site and its status.
Questions about this trial
What is this clinical trial studying?
An observational study of Monkeypox (Mpox), run by Institute of Tropical Medicine, Belgium at 1 site in Belgium.
The full registered description is in the About this study section and the official record.
Who may be eligible to take part?
The sponsor lists 4 inclusion and 1 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.
Is this clinical trial currently recruiting?
The record says: opening soon, as of the sponsor's last update on 20 Jan 2026. Status can change between updates, so confirm with the study contact before making plans.
Where is the study taking place?
The record lists 1 site in Belgium. Whether a site is taking part right now should be confirmed with that site. See every site.
What are the possible benefits and risks?
They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.
Are results available for this study?
This study is still under way. Results are not available in the source record yet.
How can a doctor refer a patient or contact the research team?
Contact Christophe Van Dijck, PhD (+32 3 345 58 65, cvandijck@itg.be), or a site near the patient. AzTrials does not enrol participants or take referrals.
What does the primary outcome measure?
Orthopoxvirus-specific serum binding and neutralising antibody titre (time frame: from enrollment to the end of follow up at 2 years). It is what the study was designed to measure, not a finding.
Where can I read the original study information?
Does a listing mean the treatment is approved or proven to work?
No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.
How often is this information updated?
AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 20 Jan 2026.